Skip to main content

Table 2 Incidences of primary effectiveness outcomes in patients receiving TKA

From: Venous thromboembolism after total joint arthroplasty: results from a Japanese multicenter cohort study

 

Fondaparinux

Enoxaparin

UFH

Others

Medication (-)

Total

n = 360 (%)

n = 223 (%)

n = 72 (%)

n = 45 (%)

n = 594 (%)

n = 1,294 (%)

All venous thromboembolism

61 (16.9)

59 (26.5)

24 (33.3)

12 (26.7)

158 (26.6)

314 (24.3)

  Any DVT (up to POD10 )

60 (16.7)

59 (26.5)

24 (33.3)

12 (26.7)

158 (26.6)

314 (24.3)

  Symptomatic DVT

2 (0.6)

3 (1.3)

0

1 (2.2)

6 (1.0)

12 (0.9)

   Distal

1 (0.3)

2 (0.9)

0

1 (2.2)

4 (0.7)

8 (0.6)

   Proximal

1 (0.3)

1 (0.4)

0

0

2 (0.3)

4 (0.3)

  Non-symptomatic DVT

59 (16.4)

56 (25.1)

24 (33.3)

11 (24.4)

152 (25.6)

302 (23.3)

   Distal

51 (14.2)

52 (23.3)

21 (29.2)

11 (24.4)

133 (22.4)

268 (20.7)

   Proximal

8 (2.2)

4 (1.8)

3 (4.2)

0

19 (3.2)

34 (2.6)

  PE (up to POD28)

1 (0.3)

0

0

0

1 (0.2)

2 (0.2)

  1. CI, confidence interval; DVT, deep vein thrombosis; PE, pulmonary embolism; POD, post-operative day; TKA, total knee arthroplasty; UFH, unfractionated heparin.